United States - English - NLM (National Library of Medicine)

alk-abello, inc. - sarocladium strictum (unii: 3f36v0451w) (sarocladium strictum - unii:3f36v0451w) - sarocladium strictum 0.05 g in 1 ml - hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust, molds, animal danders, various other inhalants, and in situations where the offending allergen cannot be avoided. prior to initiation of therapy, the clinical sensitivity should be established by careful evaluation of the patient’s history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can easily be avoided. a patient should not be immunized with preparations of allergens to which the patient has not demonstrated symptoms, ige antibodies, positive skin tests, or properly controlled challenge testing. in most cases, immunotherapy is not indicated for those allergens that can be eliminated or minimized by environmental control. patients on beta-blockers are not candidates for immunotherapy, as they can be non-responsive to beta-agonists that may be required to reverse a systemic reaction (also see warnings and adverse

United States - English - NLM (National Library of Medicine)

cardinal health 414, llc - radium ra-223 dichloride (unii: rj00kv3vtg) (radium ra-223 cation - unii:9h414a99md) - radium ra-223 dichloride 90 uci in 1 ml

United States - English - NLM (National Library of Medicine)

bayer healthcare pharmaceuticals inc. - radium ra-223 dichloride (unii: rj00kv3vtg) (radium ra-223 cation - unii:9h414a99md) - radium ra-223 dichloride 30 uci in 1 ml - xofigo is indicated for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease. none. the safety and efficacy of xofigo have not been established in females. based on mechanism of action, xofigo can cause fetal harm when administered to a pregnant female [see clinical pharmacology ( 12.1)] . while there are no human or animal data on the use of xofigo in pregnancy, maternal use of a radioactive therapeutic agent could affect development of a fetus. advise pregnant females and females of reproductive potential of the potential risk to a fetus. risk summary the safety and efficacy of xofigo have not been established in females. there is no data on the presence of radium-223 dichloride in human milk, the effects on the breastfed child, or the effects on milk production. males because of potential effects on spermatogenesis associated with radiation, advise male patients to use condoms and their female partners of reproductive potential to use effective contraception during and for 6 months after completing treatment with xofigo [see use in specific populations (8.1)] . males based on mechanism of action, xofigo may impair fertility in males of reproductive potential [see clinical pharmacology (12.1) and nonclinical toxicology (13.1)] . the safety and efficacy of xofigo in pediatric patients have not been established. in single- and repeat-dose toxicity studies in rats, findings in the bones (depletion of osteocytes, osteoblasts, osteoclasts, fibro-osseous lesions, disruption/disorganization of the physis/growth line) and teeth (missing, irregular growth, fibro-osseous lesions in bone socket) correlated with a reduction of osteogenesis that occurred at clinically relevant doses beginning in the range of 22 – 88 kbq (0.59 - 2.38 microcurie) per kg body weight. of the 600 patients treated with xofigo in the randomized trial, 75% were 65 years of age and over and while 33% were 75 years of age and over. no dosage adjustment is considered necessary in elderly patients. no overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. no dedicated hepatic impairment trial for xofigo has been conducted. since radium-223 is neither metabolized by the liver nor eliminated via the bile, hepatic impairment is unlikely to affect the pharmacokinetics of radium-223 dichloride [see clinical pharmacology (12.3)] . based on subgroup analyses in the randomized clinical trial, dose adjustment is not needed in patients with mild hepatic impairment. no dose adjustments can be recommended for patients with moderate or severe hepatic impairment due to lack of clinical data. no dedicated renal impairment trial for xofigo has been conducted. based on subgroup analyses in the randomized clinical trial, dose adjustment is not needed in patients with existing mild (creatinine clearance [crcl] 60 to 89 ml/min) or moderate (crcl 30 to 59 ml/min) renal impairment. no dose adjustment can be recommended for patients with severe renal impairment (crcl less than 30 ml/min) due to limited data available (n = 2) [see clinical pharmacology (12.3)] .

Canada - English - Health Canada

biologische heilmittel heel gmbh - palladium - liquid - 6d - palladium 6d - homeopathic products

Canada - English - Health Canada

biologische heilmittel heel gmbh - palladium - liquid - 12d - palladium 12d - homeopathic products

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - radium (223ra) dichloride, quantity: 6600 kbq - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium chloride; sodium citrate dihydrate - xofigo is indicated for the treatment of castration-resistant prostate cancer patients with symptomatic bone metastases and no known visceral metastatic disease.

Canada - English - Health Canada

boiron laboratoires - palladium - drops - 4ch - palladium 4ch - homeopathic products

Canada - English - Health Canada

boiron laboratoires - palladium - tablet - 4ch - palladium 4ch - homeopathic products

Canada - English - Health Canada

dolisos laboratoires s.a. - palladium - drops - 3ch - palladium 3ch - homeopathic products

Canada - English - Health Canada

homeocan inc. - palladium - tablet - 4ch - palladium 4ch - homeopathic products